Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069
1997

Enhanced Sensitivity to Tirapazamine and RSU 1069 through P450 Reductase Overexpression

Sample size: 6 publication Evidence: moderate

Author Information

Author(s): AV Patterson, MP Saunders, EC Chinje, DC Talbot, AL Harris, IJ Strafford

Primary Institution: Medical Research Council, Harwell, Didcot, Oxon OX11 ORD, UK

Hypothesis

Does overexpression of P450 reductase increase sensitivity to the bioreductive drugs tirapazamine and RSU 1069 in breast cancer cells?

Conclusion

The study found that breast cancer cells with higher P450 reductase activity showed increased sensitivity to tirapazamine and RSU 1069, especially under hypoxic conditions.

Supporting Evidence

  • Transfected clones showed up to a 53-fold increase in P450 reductase activity.
  • Activity of P450 reductase correlated with both hypoxic and aerobic toxicity of tirapazamine.
  • Measurable P450 reductase activity was found in 14 primary human breast tumors.

Takeaway

If certain breast cancer cells have more of a specific protein, they can be hurt more by certain medicines when there's less oxygen around.

Methodology

The study involved transfecting the MDA231 breast cancer cell line with human P450 reductase cDNA and assessing drug sensitivity and enzyme activity.

Limitations

The study primarily focused on a limited number of cell lines and may not fully represent all breast cancer types.

Participant Demographics

Human breast cancer cell lines were used, specifically the MDA231 line.

Statistical Information

P-Value

0.003

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication